Table 1.
Patient Demographics, Histological Analysis, Clinical Notes, and Serum Levels of AST, ALT, ALP, γ-GT, and Total Bilirubin
| Diagnosis | Age, years | Sex | BMI, kg/m2 | Race | AST, U/L | ALT, U/L | ALP, U/L | γ-GT, U/L | Total bilirubin, U/L | Histologic analysis | Clinical notes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Control | 51 | F | 27.916 | White | 41 | 49 | 86 | 42 | 1.1 | NA | NA |
| Control | 34 | F | 25.965 | White | 132 | 51 | 51 | 119 | 0.5 | NA | NA |
| Control | 25 | M | 23.291 | Asian | 47 | 27 | 73 | 21 | 0.5 | NA | NA |
| Control | 42 | M | 32.216 | Asian | 50 | 35 | 43 | 34 | 0.5 | NA | NA |
| Control | 44 | M | 28.278 | White | 62 | 22 | 95 | 53 | 2.4 | NA | NA |
| NAFLD | 70 | F | 28.4 | Hispanic | 63 | 78 | 141 | NA | 0.7 | F1-F2 fibrosis; A0-A1 inflammation | Diagnosed as having NAFLD in 2015 |
| NAFLD | 18 | F | 33.64 | White | 122 | 362 | 92 | 29 | 0.3 | F0 fibrosis; A3 inflammation | Diagnosed as having NAFLD in 2017 |
| NAFLD | 57 | F | 27.9 | Hispanic | 65 | 55 | 83 | 19 | 0.4 | F0-F1 fibrosis; A0-A1 inflammation | Diagnosed as having NAFLD in 2017 |
| NAFLD | 54 | M | 33.18 | Hispanic | 43 | 60 | 62 | 35 | 1.3 | NA | Diagnosed as having NAFLD in 2017; fatty liver on ultrasonography |
| NASH | 45 | M | 25.6 | Hispanic | 21 | 32 | 117 | 38 | 5.1 | Liver stage grade 1; inflammation stage 3–4; fibrosis, focal ballooning degeneration, 5% macrovesicular steatosis | NASH diagnosed 13 years before liver transplantation in 2016 |
| NASH | 55 | M | 23.52 | White | 56 | 31 | 141 | 32 | 1.6 | Grade 4 fibrosis, chronic portal inflammation | NASH diagnosed 3 years before liver transplantation in 2016 |
| NASH | 58 | F | 35.2 | Hispanic | 241 | 123 | 111 | NA | 33.7 | Grade 4 fibrosis/cirrhosis, mild patchy steatosis, cholestasis | NASH diagnosed 9 years before liver transplantation in 2016, history of gastric bypass attributable to morbid obesity |
| NASH | 62 | M | 31.82 | Hispanic | 24 | 11 | 109 | NA | 0.5 | Inflammation grade 1, fibrosis grade 1,no ballooning degeneration | NASH diagnosed in 2015, underwent colon resection and liver biopsy in 2016 |
| HCV | 55 | M | 21.6 | White (Arab) | 37 | 60 | 168 | NA | 0.2 | Chronic hepatitis grade 2/stage 4 fibrosis | Status post liver resection for HCC |
| HCV | 55 | M | 42.16 | White | 90 | 64 | 172 | NA | 2.9 | Grade 2/stage 4 | Liver transplantation |
| NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | Liver transplantation |
| ALD | 55 | M | 30.07 | Hispanic | 68 | 59 | 155 | NA | 2 | Grade 2/stage 4 | Liver transplantation |
| Liver transplant rejection | 47 | M | 21 | White | 64 | 30 | 990 | NA | 17.2 | Scattered inflammation/stage 3 fibrosis, marked canalicular cholestasis | Liver transplantation |
| AIH | 36 | F | 34.6 | White | 348 | 236 | 89 | NA | 9.2 | AIH grade 4/stage 4 | Liver transplantation |
F, female; M, male; AIH, autoimmune hepatitis; ALD, alcoholic liver disease; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; γ-GT, γ-glutamyl transferase; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; NA, not applicable; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis.